MedPath

Brexpiprazole for the treatment of acute schizophrenia in the Japanese populatio

Phase 4
Conditions
schizophrenia
Registration Number
JPRN-UMIN000032339
Lead Sponsor
Fujita Health University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1. the patient with coma 2. the patient receiving anesthetic agent or barbiturate 3. the patient receiving epinephrine 4. the patient receiving psychostimulant 5. the patient having allergy brexpiprazole 6, the patient with DM 7. the patient with pregnancy 8. the patient with breast-feeding 9. the patient receiving clozapine 10. the patient suitable for clozapine 11. the patient who the clinician do not suggest to entry the study 12. the patient with mental retardation 13. the patient with dementia 14. the patient with personality disorder 15. the patient with organic brain disease and/or severe physical disease 16. the patient receiving paroxetine 17. the patient receiving carbamazepine 18. the patient receiving electroconvulsive therapy within 6 months before the study 19. the patient receiving long-acting injectable antipsychotics within 6 months before the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
All causes discontinuation
Secondary Outcome Measures
NameTimeMethod
Discontinuation due to adverse events, discontinuation due to inefficacy, the improvement of psychopathology, individual adverse events
© Copyright 2025. All Rights Reserved by MedPath